Pembrolizumab

Pembrolizumab

Pembrolizumab is a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 to bind to other members of the HER family.

 

[accordions]
[accordion title= “Chemical Properties“]

Molecular Weight 149 kDa
CAS No. 1374853-91-4

[/accordion]

 

[accordions]
[accordion title= “References and Literature“]

1. Khoja L, et al. Pembrolizumab. J Immunother Cancer. 2015 Aug 18;3:36.2. Garon EB, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015 May 21;372(21):2018-28.

[/accordion]